Rexulti patent expiration?

When Does the Rexulti Patent Expire?

Rexulti, also known as brexpiprazole, is an antipsychotic medication approved by the US FDA in 2015 for the treatment of schizophrenia and as an adjunctive treatment for major depressive disorder. According to DrugPatentWatch.com [1], the Rexulti patent was initially set to expire on April 7, 2023. However, the patent holders have filed various extensions, which can delay the patent's expiration date.

Why is the Patent Expiration Date Important?

The patent expiration date is significant because it will allow generic versions of Rexulti to enter the market. Generic drugs can be a more affordable alternative to the name-brand version, potentially benefiting patients and healthcare systems.

What Happens When the Patent Expires?

When the Rexulti patent expires, the first generic version of the drug will be approved and launched. According to FDA guidelines, generic drugs must demonstrate bioequivalence to the name-brand drug, ensuring their safety and effectiveness for patients. Companies like Apotex, which has filed an Abbreviated New Drug Application (ANDA) for brexpiprazole [2], may be among the first to market their generic versions.

When Can Patients Expect Generic Rexulti Options?

Given the complexities of the patent process and potential appeals, it is challenging to pinpoint an exact date for generic Rexulti's availability. However, we can anticipate generic versions of the drug to enter the market in the coming months.

What Are the Implications for Patients and Healthcare Professionals?

The availability of generic Rexulti will likely reduce costs associated with treating patients, which can be a significant advantage for insurance companies, patients, and healthcare providers. It is essential for patients and prescribers to consult with their healthcare providers and insurance providers to ensure a smooth transition to the generic version.

Sources

[1] DrugPatentWatch.com: Brexpiprazole Patent
[2] FDA: ANDA for Brexpiprazole by Apotex

Sources:

1. DrugPatentWatch.com: Brexpiprazole Patent
2. FDA: ANDA for Brexpiprazole by Apotex